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Abstract A recombinant soluble form of the catalytic domain of
human ADAM-10 was expressed as an Fc fusion protein from
myeloma cells. The ADAM-10 was catalytically active, cleaving
myelin basic protein and peptides based on the previously
described ‘metallosheddase’ cleavage sites of tumour necrosis
factor K, CD40 ligand and amyloid precursor protein. The
myelin basic protein degradation assay was used to demonstrate
that hydroxamate inhibitors of matrix metalloproteinases
(MMPs) were also inhibitors of ADAM-10. The natural MMP
inhibitors, TIMP-2 and TIMP-4 were unable to inhibit ADAM-
10, but TIMP-1 and TIMP-3 were inhibitory. Using a quenched
fluorescent substrate assay and ADAM-10 we obtained approx-
imate apparent inhibition constants of 0.1 nM (TIMP-1) and
0.9 nM (TIMP-3). The TIMP-1 inhibition of ADAM-10 could
therefore prove useful in distinguishing its activity from that of
TACE, which is only inhibited by TIMP-3, in cell based assays.
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1. Introduction
The ADAMs are type I membrane proteins containing a
disintegrin and a metalloproteinase domain [1]. ADAMs are
predicted to be involved in important cellular events, includ-
ing cellular adhesion and membrane protein shedding [2,3].
The latter role concerns the ADAMs that are likely to be
active proteases based on the integrity of their active site [4].
Approximately half of the ADAMs identi¢ed fall into this
category, thereby forming a branch of the metzincin super-
family of metalloproteinases which also includes the matrix
metalloproteinases (MMPs) [5]. In particular, ADAM-17,
also known as the tumour necrosis factor-K (TNF-K) convert-
ing enzyme (TACE), sheds membrane-anchored TNF-K gen-
erating its soluble form [6,7]. More recently, TACE has been
suggested to be involved in the shedding of other membrane
proteins. In common with as yet unidenti¢ed ‘sheddases’,
TACE is inhibited by synthetic inhibitors (MMP inhibitors;
MMPIs) originally designed to target MMPs and is upregu-
lated by activators of protein kinase C, such as phorbol myr-
istate acetate [8].
The X-ray crystal structure of the catalytic domain of hu-
man TACE suggested that the structure of the active site not
only allowed MMPIs to bind e⁄ciently, but also, theoreti-
cally, the tissue inhibitors of MMPs (TIMPs) [9]. In practice,
only TIMP-3 out of the four TIMPs tested could e⁄ciently
inhibit TACE [10]. In parallel, other studies showed that
TIMP-3 was able to block the cellular shedding of proTNF-
K, L-selectin and the interleukin-6 (IL-6) receptor [11,12]. Re-
cently, other TIMPs have been shown to share the ability to
inhibit membrane protein proteolysis. In particular, TIMP-2
also inhibited the shedding of the TNF receptors [13], whereas
TIMP-1 was found to prevent the shedding of the heparin-
binding epidermal growth factor (HB-EGF) and the tyrosine
kinase receptor HER-2 [14,15]. These observations implicate
the involvement of metallosheddases that can be distinguished
from TACE through their di¡ering sensitivity to TIMPs.
In this study, we examine the proteolytic activity and inhi-
bition characteristics of ADAM-10. ADAM-10 was initially
cloned from bovine brain and was found to be expressed in a
wide variety of tissues [16]. ADAM-10 not only shares a closer
sequence similarity and potential structural features with
TACE than with any other mammalian ADAM [3] but it is
also able to cleave TNF-K based TACE substrates [17]. Both
enzymes have also been shown to cleave peptides based on the
K-secretase-sensitive sequence of amyloid precursor protein
[18,19]. Puri¢ed ADAM-10 is able to degrade myelin basic
protein (MBP) and type IV collagen, although it remains to
be determined whether these activities are relevant in vivo
[16,20,21]. The Drosophila ADAM-10 orthologue KUZ has
been linked to the processing of the Notch receptor ligand
Delta and is thus implicated in cell fate determination [22].
However, it is not known whether ADAM-10 shares the abil-
ity of KUZ to cleave Notch receptor ligands.
In this report, the catalytic activity of recombinant human
ADAM-10 has been assayed to characterise its sensitivity to-
wards MMPIs and TIMPs. Such data are relevant to the
analysis of the inhibitory pro¢le of cell surface shedding
events mediated by metalloproteinases. The substrate speci¢c-
ity of ADAM-10 towards peptides mimicking the membrane-
proximal cleavage site of proteins shed by metalloproteinases
was also investigated.
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2. Materials and methods
2.1. Materials and general procedures
Protein A and soya bean trypsin inhibitor-conjugated Sepharose
and all other non-speci¢ed reagents were from Sigma (Poole, UK).
Recombinant enterokinase was from Novagen (Cambridge Bio-
science, Cambridge, UK). Recombinant human TIMPs-1, -2 and -3
were expressed in NS0 mouse myeloma cells and puri¢ed as previ-
ously described [23]. Full-length mouse TIMP-4 was expressed from
Escherichia coli and refolded (V. Kna«uper, unpublished). The broad-
spectrum MMPI BB94 was a kind gift from British Biotech Pharma-
ceuticals Ltd. (Oxford, UK). The peptides Ac-KENSFEMQKGAQ-
NH2 (CD40L), Ac-LPPVAASSLR-NH2 (KL1) and Ac-GLSLPV-
ENRLYTYD-NH2 (HB-EGF) were respectively based on the cleav-
age site of the juxtamembrane region of the cytokines CD40-ligand
and c-kit ligand-1 and the growth factor HB-EGF. These peptides
were a kind gift from R. Black (Immunex Corp. Ltd., Seattle, WA,
USA). The peptides H-YEVHHQKLVFF-OH, based on the K-secre-
tase cleavage site of APP, and H-YGSLPQKAQRPQDEN-OH, based
on the ADAM-10 cleavage site of MBP, were from Bachem (Buben-
dorf, Switzerland).
Fluorimetric measurements were made with a Perkin-Elmer LS50B
spectro£uorimeter (Vex = 328 nm, Vem = 393 nm) at 37‡C in 2.5 ml of
bu¡er A (10 mM HEPES, pH 7.5, 0.02% NaN3, 0.05% Brij 35) con-
taining a constant amount of dimethylsulfoxide (DMSO) (1% v/v).
The quenched £uorescent substrate (7-methoxycoumarin-4-yl)ace-
tyl-Ser-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Lys(2,4-dinitro-
phenyl)-NH2 (QF45), based on the TACE-sensitive sequence in hu-
man TNF-K, were as previously described [10].
High performance liquid chromatography (HPLC) analyses were
done on a Perkin-Elmer Integral 4000 instrument equipped with a
Vydac 218TP54 column maintained at 40‡C. Solvents were: A,
0.1% tri£uoroacetic acid (TFA) in water; B, 0.08% TFA in acetoni-
trile. A linear gradient from 5 to 95% B was run over 20 min at
1.25 ml/min and the eluate was monitored at 230 nm.
2.2. Expression and puri¢cation of recombinant ADAM-10
A full-length cDNA for ADAM-10 was isolated from the human T
cell line Jurkat (ECACC Ref. No.: 88042803), essentially as previ-
ously described [10]. The DNA fragment encoding the pre pro cata-
lytic domain was ampli¢ed by PCR and a 5P HindIII and Kozak
sequence upstream of the initiating methionine codon and a 3P SalI
site were introduced. The coding sequence was then ligated into the
vector pEE12 [10] such that it was joined at the SalI site to a sequence
encoding the human IgG1 heavy chain constant region, hinge, CH2
and CH3 domains. A DNA adapter encoding an enterokinase cleav-
age site ([V]DDDDK) was further introduced at the SalI site. The
vector was transfected into mouse NS0 myeloma cells and clones
expressing recombinant protein were identi¢ed and grown as previ-
ously described [10].
For puri¢cation of recombinant ADAM-10, the transfected NS0
cells were grown in conditioned medium containing the MMPI
BB94 (1 WM) to prevent proteolytic degradation of ADAM-10 cata-
lytic domain Fc fusion, as previously reported [17]. After binding of
the fusion protein (rADAM-10) to protein A-Sepharose, the gel was
washed with 50 volumes of bu¡er A. rADAM-10 was eluted with ¢ve
volumes of 100 mM glycine, pH 3.0, and immediately neutralised with
1 M Tris, pH 7.5. The absence of BB94 after puri¢cation was checked
using an MMP-2 £uorimetric activity assay [24].
2.3. Enzyme assays
The active site concentration and inhibition of ADAM-10 estimated
with TIMP-1 and TIMP-3 as well as the activity assay with the
quenched £uorescent peptide QF45 were as previously described for
TACE [10]. rADAM-10 (150 nM) was incubated at 37‡C with MBP
(500 Wg/ml) or peptides (50 WM) in bu¡er A containing a constant
amount of DMSO (1% v/v). MBP and enzyme mixtures were incu-
bated for 4 h and then analysed by 14% sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) under reduced condi-
tions. Peptide cleavage reactions were stopped at di¡erent times by
dropping the pH to 4. The samples (100 Wl) were then analysed by
HPLC. The fragment peaks were collected and identi¢ed by mass
spectrometry. The catalytic speci¢cities (kcat/KM) for the cleavage of
peptides were obtained by measuring the HPLC peak areas of start
and end products at early time points so that less than 10% of the
peptide substrate was turned over.
3. Results and discussion
3.1. Puri¢cation of rADAM-10
The material eluted from protein A-Sepharose yielded two
bands of Mr 65 and 31 kDa on SDS^PAGE (Fig. 1B, lane 1).
These two protein species contained the Fc fusion domain as
they were both detected with an anti-human Fc antibody by
Western blotting (Fig. 1B, lane 2). This observation combined
with predicted molecular weights for the domains of rADAM-
10 suggested that the 65 and 31 kDa proteins correspond to
the Fc with and without the catalytic domain of rADAM-10.
Thus, as previously observed by Rosendahl et al., rADAM-10
was partially cleaved, most likely at the proteolytically sensi-
tive Fc hinge region [17]. The 65 kDa band was no longer
observed on SDS^PAGE and Western blots if the MMPI
BB94 was omitted from the conditioned medium, indicating
that the proteolytic cleavage of the Fc hinge region is at least
partially metalloproteinase-mediated. We propose that this
process might be autocatalytic, as BB94 e⁄ciently inhibits
ADAM-10 catalytic activity (J.D. Becherer, personal commu-
nication).
Fig. 1. SDS^PAGE analysis of puri¢ed rADAM-10. (A) Schematic
representation of the ADAM-10 pre pro catalytic domain expressed
as a Fc fusion, the arrow indicates where a furin-like proteinase is
likely to activate ADAM-10. (B) SDS^PAGE of puri¢ed rADAM-
10. The fusion protein was bound to protein A-Sepharose and
eluted under acid conditions: lane 1, Coomassie blue-stained; lane
2, Western blot using an anti-human Fc antibody.
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3.2. MBP degrading activity of rADAM-10
To determine whether rADAM-10 was catalytically active,
the puri¢ed material was incubated with MBP and its cleavage
monitored by SDS^PAGE, as described by [20]. After a 4 h
incubation, the 20 kDa MBP was completely degraded with
the appearance of two prominent protein bands of about 9
and 11 kDa (Fig. 2A) consistent with previous reports [16,21].
Glynn and collaborators also determined the site for the ini-
tial cleavage of MBP by puri¢ed bovine ADAM-10 which
occurred at the Pro-73^Gln-74 bond [25]. A MBP-based pep-
tide substrate was cleaved by rADAM-10 at the Pro^Gln
bond, con¢rming that the substrate speci¢city of rADAM-
10 mimicked that of puri¢ed bovine ADAM-10 (Table 1).
3.3. Catalytic activity of rADAM-10 towards peptide
substrates
Several di¡erent types of intrinsic proteins are released from
the plasma membrane by metalloproteases. To evaluate fur-
Fig. 2. A: MBP degradation by rADAM-10. Bovine MBP was incubated at 37‡C for 4 h with rADAM-10. Reactions were stopped by the ad-
dition of sample bu¡er followed by heating and analysed by 14% SDS^PAGE under reduced conditions. Lanes 1 and 2: 10 Wl of MBP alone
before (1) and after incubation (2). Lanes 3^18: 10 Wl of incubation mixture containing rADAM-10 (0.15 WM) and MBP (0.5 mg/ml) with 1%
(v/v) DMSO (3), 10 mM 1,10-phenanthroline (4), 0.25 WM TIMP-1, -2, -3 or -4 (5^8), 5 WM CT435, CT572, CT635, CT1399, CT1847 or
CT2256 (9^14). B: MMPIs tested on ADAM-10 with inhibition constants versus selected MMPs.
Table 1
Peptides mimicking the membrane-proximal cleavage site of proteins
shed by metalloproteases were evaluated for cleavage by rADAM-
10
Substrate Peptide ADAM-10
CD40L KENSFE*MQKGAQ KENSFEMsQKGAQ
0.5U103
APP YEVHHQK*LVFF YEVHHQKsLVFF
0.7U103
TNF-K SPLAQA*VRSSSR SPLAQAsVRSSSR
2.0U103
MBP YGSLP*QKAQRPQDEN YGSLPsQKAQRPQDEN
0.9U103
The predicted cleavage site is between the two residues represented
by an asterisk and the observed cleavage sites are indicated with an
arrow (s). The rates of peptide turnover were determined by HPLC
and are reported as kcat/KM (M31 s31) with S.E.M. below 30%.
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ther the cleavage speci¢city of ADAM-10, the recombinant
proteins were incubated with peptides corresponding to cleav-
age sites of speci¢c membrane proteins that are known to be
released by metalloproteases [8]. rADAM-10 was able to
cleave both the TNF-K and APP peptides at the correct cleav-
age site, as previously reported [17,18]. The TNF-K-based
peptide QF45 was two orders of magnitude less sensitive for
ADAM-10 than for TACE [10]. The peptides based on the
cleavage site of the juxtamembrane region of the cytokine c-
kit ligand-1 and the growth factor HB-EGF were not cleaved
by rADAM-10. The CD40L (also known as TRAP or
CD154)-based peptide [26] was hydrolysed by ADAM-10,
but at a di¡erent site than the one expected for the CD40L
sheddase (Table 1).
3.4. Inhibition of rADAM-10 activity
The MBP degradation assay was also used to evaluate the
inhibitory potential of MMPIs as well as TIMPs towards
rADAM-10. Of the six hydroxamate-based MMPIs tested
(Fig. 2B), only CT635 did not inhibit rADAM-10. From
this, it appears that ADAM-10 inhibition is not a¡ected by
the length of the side-chain in position P1P and this contrasts
with the observation that sheddases are usually only inhibited
by hydroxamate inhibitors with an isobutyl group in that
position [8]. In that respect, ADAM-10 resembles more
MMP-2 or MMP-3 than MMP-1 or TACE (Fig. 2B, [10]).
Importantly, the rADAM-10-catalysed degradation of
MBP was abolished with low submicromolar concentrations
of both TIMP-1 and -3. This was con¢rmed using the
quenched £uorescent TACE substrate, QF45. TIMP-1 and
-3 behaved as active site titrants, con¢rming that they are
both potent inhibitors of rADAM-10. However, for
rADAM-10, the QF45 assay was not sensitive enough (kcat/
KM = 2U103 M31 s31) to allow the accurate estimation of
apparent inhibition constants (KiP). The lowest enzyme con-
centration used to monitor activity (4 nM) still exceeded the
KiP values estimated for TIMP-1 (0.1 nM) and TIMP-3
(0.9 nM). Thus, although both TACE and ADAM-10 are
prone to TIMP-3 inhibition, these enzymes are distinguished
by a di¡erent susceptibility to TIMP-1. TIMP-1 was e⁄cient
in inhibiting rADAM-10-induced MBP degradation at con-
centrations similar to those used to inhibit aggrecan degrada-
tion by the soluble disintegrin metalloproteinase ADAM-TS4
[27]. As TIMP-2 was inactive on ADAM-TS4, it would be
interesting to determine the e¡ect of TIMP-3 on this enzyme
and how it compares to ADAM-10 and TACE.
The TIMP-1 inhibition of ADAM-10 could prove useful in
distinguishing its activity from that of TACE in cell-based
assays. The lack of TIMP-1 inhibition for the shedding of
proTNF-K, L-selectin and the receptors to the cytokines
TNF-K and IL-6 [11,13] precludes the participation of
ADAM-10 in the solubilisation of these membrane proteins.
Controversially, TIMP-1 can inhibit the shedding of the tyro-
sine kinase receptor HER-2 [15], as well as the growth factor
HB-EGF [15], but our peptide cleavage data suggest that the
latter may not be processed by ADAM-10. ADAM-10 and
TACE share some structural similarities which distinguish
them from the other ADAMs and, to date, appear to have
a more general proteolytic capacity [3]. It could be hypothe-
sised that these two ADAMs are more susceptible to TIMP
inhibition because of their special structure, a topic which is
under detailed investigation.
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